UCB'S ANNOUNCES RESULTS OF CIMZIA FOR PSORIASIS

UCB has announced significant positive results from the first study to evaluate the efficacy and safety of Cimzia (certolizumab pegol, CDP870), a new type of anti-tumor necrosis factor (anti-TNF) therapy, in the treatment of patients with moderate to severe psoriasis.

The Phase II, randomized, double-blind, placebo-controlled dose-ranging study involved 176 patients with moderate to severe chronic plaque psoriasis who were candidates for systemic therapy and/or photo- or photochemo-therapy. The patients were randomized to one of two different subcutaneous dosing regimens using the liquid formulation: Cimzia 400 mg given every other week, or an initial dose of 400 mg followed by a dose of 200 mg given every other week, or placebo.